General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Non-metastatic Castration-resistant prostate cancer
Last updated July 9, 2019
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer
Last updated July 8, 2019
Status:
Concluded with an LOI
Manufacturer:
Eisai Limited
Indication:
Epilepsy, primary generalized tonic-clonic seizures
Last updated July 2, 2019
Status:
Concluded with an LOI
Manufacturer:
Biogen Canada Inc.
Indication:
Spinal Muscular Atrophy
Last updated June 26, 2019
Status:
Concluded without agreement
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Severe Persistent Asthma
Last updated June 25, 2019
Status:
Concluded with an LOI
Manufacturer:
Allergan Inc.
Indication:
Conception Control
Last updated June 21, 2019
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated June 21, 2019
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Secondary Prevention of Atherothrombotic Events
Last updated June 19, 2019
Status:
Negotiations were not pursued
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Onychomycosis
Last updated June 19, 2019
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
HIV-1 Infection
Last updated June 14, 2019